Deep-Learning-Based Analysis of Disease-Specific Structural Biomarkers on Retinal Sensitivity in Neovascular Age-Related Macular Degeneration

基于深度学习的疾病特异性结构生物标志物对新生血管性年龄相关性黄斑变性视网膜敏感性的影响分析

阅读:1

Abstract

PURPOSE: To evaluate the impact of disease-specific biomarkers on pointwise sensitivity (PWS) in patients with active neovascular age-related macular degeneration (nAMD) using two microperimetry (MP) instruments. METHODS: Participants in this prospective cross-sectional study underwent imaging with a SPECTRALIS HRA+OCT and MP with the photopic MP-3 (NIDEK) and mesopic MAIA (CenterVue). Pigment epithelium detachment (PED), intraretinal and subretinal fluid (IRF, SRF), ellipsoid zone loss (EZL), and subretinal hyperreflective material (SHRM) were quantified using deep learning (DL). DL enabled co-registration between the MP and optical coherence tomography (OCT). Univariate and multivariable mixed-effects models using variable selection including interaction terms were used to assess the effects of the biomarkers on PWS. RESULTS: Twenty eyes of 20 subjects (mean age, 76.0 years) were included. Sensitivity in the MAIA was lower (-2.87 dB; 95% confidence interval [CI], -3.15 to -2.59) than in the MP-3. Significant interactions between EZL and SRF, EZL and IRF, and between EZL and eccentricity were observed. EZL significantly reduced PWS (-1.30 dB; 95% CI, -2.08 to -0.51) at 0° eccentricity with SRF of 0.15 nL and absent IRF. IRF presence further decreased PWS by -2.57 dB (95% CI, -3.66 to -1.47). SRF negatively impacted PWS (-2.08 dB/nL; 95% CI, -2.53 to -1.64), but showed no association when EZL was present (+0.05 dB/nL; 95% CI, -0.81 to 0.92). SHRM presence and PED volume reduced PWS by -5.13 dB (95% CI, -5.83 to -4.43) and -0.71 dB/nL (95% CI, -0.92 to -0.50), respectively. Eccentricity only impaired function in the presence of EZL (-0.49 dB/°; 95% CI, -0.61 to -0.37). CONCLUSIONS: DL-quantified biomarkers mostly had a negative impact on PWS in nAMD, particularly IRF and SHRM presence. The above-mentioned biomarkers should be considered when managing patients with nAMD and using MP in trials and clinical settings.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。